73

Oncology
Prevention and treatment of tumors, and caring for cancer patients.
Sub Categories on Oncology
Latest Articles
Inequities seen in cancer treatment delay in patients with SARS-CoV-2

Inequities seen in cancer treatment delay in patients with SARS-CoV-2

by Elana GotkineRace and ethnicity and area-level social determinants of health (SDOH) are associated with delayed or discontinued cancer treatment among patients with severe acute respiratory syndrom

Inequities seen in cancer treatment delay in patients with SARS-CoV-2

by Elana GotkineRace and ethnicity and area-level social determinants of health (SDOH) are associated with delayed or discontinued cancer treatment among patients with severe acute respiratory syndrom
Daratumumab Plus Induction Therapy Reduces Stem Cell Yield in Multiple Myeloma

Daratumumab Plus Induction Therapy Reduces Stem Cell Yield in Multiple Myeloma

June 9, 2023Tony Berberabe, MPHThe addition of daratumumab to frontline induction therapy prior to peripheral blood stem cell collection reduced the number of patients with newly diagnosed multiple my

Daratumumab Plus Induction Therapy Reduces Stem Cell Yield in Multiple Myeloma

June 9, 2023Tony Berberabe, MPHThe addition of daratumumab to frontline induction therapy prior to peripheral blood stem cell collection reduced the number of patients with newly diagnosed multiple my
Significant treatment attrition rate seen in multiple myeloma

Significant treatment attrition rate seen in multiple myeloma

by Elana GotkineThere is a significant treatment attrition rate in newly diagnosed multiple myeloma (NDMM), according to a study published in the November issue ofLeukemia & Lymphoma.Victor

Significant treatment attrition rate seen in multiple myeloma

by Elana GotkineThere is a significant treatment attrition rate in newly diagnosed multiple myeloma (NDMM), according to a study published in the November issue ofLeukemia & Lymphoma.Victor
New study supports extending cervical screening intervals for people who test negative for HPV

New study supports extending cervical screening intervals for people who test negative for HPV

byAlice Davies| Analysis1 June 2022Normal squamous epithelial cells from the cervix under the microscopeIn January, we wrote about thechanges to the cervical screening programme in W

New study supports extending cervical screening intervals for people who test negative for HPV

byAlice Davies| Analysis1 June 2022Normal squamous epithelial cells from the cervix under the microscopeIn January, we wrote about thechanges to the cervical screening programme in W
Novel drug shows promising efficacy for patients with multiple myeloma

Novel drug shows promising efficacy for patients with multiple myeloma

by Jenny Owen,Emory UniversityScanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Credit: NIAIDResults of an international clin

Novel drug shows promising efficacy for patients with multiple myeloma

by Jenny Owen,Emory UniversityScanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Credit: NIAIDResults of an international clin
Hormonal breast cancer treatment reduces long-term risk of recurrence

Hormonal breast cancer treatment reduces long-term risk of recurrence

byKarolinska InstitutetCredit: Unsplash/CC0 Public DomainTo investigate the long-term benefit of hormone-lowering treatment, researchers at Karolinska Institutet have done a 20-year follow-up of

Hormonal breast cancer treatment reduces long-term risk of recurrence

byKarolinska InstitutetCredit: Unsplash/CC0 Public DomainTo investigate the long-term benefit of hormone-lowering treatment, researchers at Karolinska Institutet have done a 20-year follow-up of
Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

June 27, 2023Kristi RosaFixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lympho

Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

June 27, 2023Kristi RosaFixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lympho
Targeting enzyme could alleviate muscle wasting for cancer patients

Targeting enzyme could alleviate muscle wasting for cancer patients

byUniversity of Texas Health Science Center at HoustonCredit: Pixabay/CC0 Public DomainTargeting a specific enzyme in the muscle could help cancer patients preserve muscle mass and potentially p

Targeting enzyme could alleviate muscle wasting for cancer patients

byUniversity of Texas Health Science Center at HoustonCredit: Pixabay/CC0 Public DomainTargeting a specific enzyme in the muscle could help cancer patients preserve muscle mass and potentially p
Cell therapy could improve bone marrow transplant safety

Cell therapy could improve bone marrow transplant safety

by Tiare Dunlap,University of California, Los AngelesGraphical abstract. Credit:iScience(2022). DOI: 10.1016/j.isci.2022.104859UCLA researchers report a step forward in the developme

Cell therapy could improve bone marrow transplant safety

by Tiare Dunlap,University of California, Los AngelesGraphical abstract. Credit:iScience(2022). DOI: 10.1016/j.isci.2022.104859UCLA researchers report a step forward in the developme
PAD4 inhibition in neutrophils halts cancer progression and metastasis

PAD4 inhibition in neutrophils halts cancer progression and metastasis

byThe Wistar InstituteCancer Cell Dividing. Credit: The Wistar InstituteResearchers in the laboratory of Yulia Nefedova, M.D., Ph.D., at The Wistar Institute and collaborators at Jubilant Therap

PAD4 inhibition in neutrophils halts cancer progression and metastasis

byThe Wistar InstituteCancer Cell Dividing. Credit: The Wistar InstituteResearchers in the laboratory of Yulia Nefedova, M.D., Ph.D., at The Wistar Institute and collaborators at Jubilant Therap
Step forward in leukemia treatment

Step forward in leukemia treatment

by South Australian Health and Medical Research InstituteCredit: AI-generated imageAn international clinical trial involving Adelaide researchers has demonstrated the safety and efficacy of a next-gen

Step forward in leukemia treatment

by South Australian Health and Medical Research InstituteCredit: AI-generated imageAn international clinical trial involving Adelaide researchers has demonstrated the safety and efficacy of a next-gen
Talazoparib + enzalutamide beneficial in metastatic prostate cancer

Talazoparib + enzalutamide beneficial in metastatic prostate cancer

by Elana GotkineFor patients with metastatic castration-resistant prostate cancer (mCRPC), treatment with talazoparib (TALA) plus enzalutamide (ENZA) is better than placebo (PBO) plus ENZA, according

Talazoparib + enzalutamide beneficial in metastatic prostate cancer

by Elana GotkineFor patients with metastatic castration-resistant prostate cancer (mCRPC), treatment with talazoparib (TALA) plus enzalutamide (ENZA) is better than placebo (PBO) plus ENZA, according